A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity

ClinicalTrials.gov ID: NCT06259981

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06259981. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the efficacy, safety, and tolerability of GLY-200 in participants with obesity.

Study identification

NCT ID: NCT06259981
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Glyscend, Inc.; Industry
Enrollment: 75 participants

Conditions and interventions

Conditions

Obesity

Interventions

GLY-200 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 20, 2024 (Actual)
Primary completion: Oct 23, 2024 (Actual)
Completion: Oct 23, 2024 (Actual)
Last update posted: Jan 23, 2025

2024

United States locations

U.S. sites: 5
U.S. states: 4
U.S. cities: 5

Facility	City	State	ZIP	Site status
Tampa Bay Medical Research, Inc.	Clearwater	Florida	33761	—
Sensible Healthcare, LLC	Ocoee	Florida	34761	—
Tandem Clinical Research	Marrero	Louisiana	70072	—
Mercury Street Medical	Butte	Montana	59701	—
Clinical Trials of Texas, Inc.	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06259981, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 23, 2025 · Synced Nov 12, 2026